ABSTRACT
Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple
myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/
μL in the peripheral blood (PB) on the 4th day of mobilization.
Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor
(G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB
before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined.
Results: The median CD34+ cell count in PB on the 4th day was 5.2/μL (0.1-13.4), which was determined to increase 206.6-fold (31.57-
49347) to 924.80 /μL (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= – 872.2; p<0.0001). The
number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106).
Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell
collection at an effective dose and reducing the mobilization time/apheresis sessions.
Primary Language | English |
---|---|
Subjects | Clinical Sciences |
Journal Section | Original Research |
Authors | |
Publication Date | January 31, 2023 |
Published in Issue | Year 2023 Volume: 36 Issue: 1 |